Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA (2020 - 2025)

Foghorn Therapeutics has reported EBITDA over the past 6 years, most recently at -$21.7 million for Q4 2025.

  • Quarterly results put EBITDA at -$21.7 million for Q4 2025, down 9.81% from a year ago — trailing twelve months through Dec 2025 was -$74.4 million (up 13.15% YoY), and the annual figure for FY2025 was -$74.4 million, up 13.15%.
  • EBITDA for Q4 2025 was -$21.7 million at Foghorn Therapeutics, down from -$15.8 million in the prior quarter.
  • Over the last five years, EBITDA for FHTX hit a ceiling of -$13.5 million in Q3 2023 and a floor of -$29.4 million in Q1 2023.
  • Median EBITDA over the past 5 years was -$23.1 million (2021), compared with a mean of -$23.5 million.
  • Biggest five-year swings in EBITDA: crashed 64.66% in 2021 and later skyrocketed 50.74% in 2023.
  • Foghorn Therapeutics' EBITDA stood at -$29.1 million in 2021, then rose by 3.88% to -$28.0 million in 2022, then increased by 17.74% to -$23.0 million in 2023, then grew by 14.37% to -$19.7 million in 2024, then fell by 9.81% to -$21.7 million in 2025.
  • The last three reported values for EBITDA were -$21.7 million (Q4 2025), -$15.8 million (Q3 2025), and -$18.0 million (Q2 2025) per Business Quant data.